Therapeutic efficacy of MSCs thus is improved in type IV hypersensitivity, liver injury, colitis, graft-versus-host disease, and arthritis via interferon (IFN)-γ or tumor necrosis factor (TNF)-α combined with interleukin (IL)-1 [5,6]. The gene discussed is TNF; the disease is graft versus host disease.